

# Constantine Mitsiades

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/10428197/constantine-mitsiades-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

9,715  
citations

45  
h-index

77  
g-index

77  
ext. papers

10,326  
ext. citations

5.3  
avg, IF

5.14  
L-index

#	Paper	IF	Citations
75	NF-kappa B as a therapeutic target in multiple myeloma. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 16639-47	31.3	723
74	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 585-98	31.3	699
73	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , <b>2002</b> , 100, 3063-7	2.2	693
72	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , <b>2005</b> , 8, 407-19	24.3	611
71	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , <b>2003</b> , 101, 1530-4	2.2	488
70	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , <b>2006</b> , 107, 4053-62	2.2	360
69	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , <b>2001</b> , 98, 428-35	2.2	358
68	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , <b>2009</b> , 114, 371-2	2.2	331
67	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , <b>2007</b> , 109, 3177-88	2.2	314
66	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Annual Review of Medicine</i> , <b>2006</b> , 57, 33-47	17.4	289
65	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. <i>Blood</i> , <b>2009</b> , 114, 1046-52	2.2	285
64	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , <b>2004</b> , 103, 1787-90	2.2	230
63	The Akt pathway: molecular targets for anti-cancer drug development. <i>Current Cancer Drug Targets</i> , <b>2004</b> , 4, 235-56	2.8	215
62	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3518-25	2.2	213
61	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. <i>Cancer Cell</i> , <b>2009</b> , 16, 309-23	24.3	197
60	Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. <i>Blood</i> , <b>2003</b> , 102, 4504-11	2.2	194
59	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 502-7	1.9	174

58	Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 7516-21	11.5	173
57	JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 17593-6	5.4	169
56	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , <b>2004</b> , 104, 4188-93	2.2	167
55	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , <b>2003</b> , 22, 8386-93	9.2	151
54	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 686-92	6.1	142
53	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). <i>Blood</i> , <b>2007</b> , 109, 1220-7	2.2	140
52	New drugs for myeloma. <i>Oncologist</i> , <b>2007</b> , 12, 664-89	5.7	138
51	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3Kinase/AKT signaling. <i>Cancer Research</i> , <b>2003</b> , 63, 5850-8	10.1	138
50	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. <i>Blood</i> , <b>2003</b> , 102, 3379-86	2.2	131
49	Identification of genes modulated in multiple myeloma using genetically identical twin samples. <i>Blood</i> , <b>2004</b> , 103, 1799-806	2.2	120
48	MLN120B, a novel IkkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5887-94	12.9	118
47	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , <b>2004</b> , 23, 8766-76	9.2	112
46	Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 875-82	6.4	106
45	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , <b>2004</b> , 103, 3158-66	2.2	106
44	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. <i>Blood</i> , <b>2003</b> , 101, 2762-9	2.2	98
43	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 783-91	4.5	94
42	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 145-56	4.5	90
41	Proteasome Inhibition in the Treatment of Cancer. <i>Cell Cycle</i> , <b>2005</b> , 4, 289-295	4.7	77

40	New proteasome inhibitors in myeloma. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 258-66	4.4	74
39	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1053-72	3.5	73
38	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 1951-61	6.1	71
37	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , <b>2004</b> , 104, 2458-66	2.2	70
36	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. <i>Blood</i> , <b>2003</b> , 101, 3606-14	2.2	65
35	The emerging role of novel therapies for the treatment of relapsed myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2007</b> , 5, 149-62	7.3	56
34	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , <b>2004</b> , 36, 304-14	1.5	53
33	A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. <i>Blood</i> , <b>2010</b> , 115, 3772-5	2.2	52
32	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. <i>Oncogene</i> , <b>2004</b> , 23, 3597-602	9.2	49
31	The treatment of relapsed and refractory multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2007</b> , 2007, 317-23	3.1	45
30	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , <b>2015</b> , 29, 27-37	10.7	43
29	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 1165-73	3.5	42
28	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. <i>Cancer Research</i> , <b>2003</b> , 63, 8428-36	10.1	42
27	Proteasome inhibition in the treatment of cancer. <i>Cell Cycle</i> , <b>2005</b> , 4, 290-6	4.7	40
26	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. <i>Oncogene</i> , <b>2005</b> , 24, 3121-9	9.3	39
25	Proteasome inhibition as a new therapeutic principle in hematological malignancies. <i>Current Drug Targets</i> , <b>2006</b> , 7, 1341-7	3	38
24	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , <b>2005</b> , 1, 161-71	3.6	30
23	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , <b>2006</b> , 18, 598-608	4.2	29

22	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , <b>2012</b> , 4, 253-68	3.6	26
21	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , <b>2011</b> , 11, 1391-402	4.8	26
20	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2010</b> , 8 Suppl 1, S4-S12	7.3	26
19	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , <b>2018</b> , 15, 1033-1052	1.5	25
18	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , <b>2010</b> , 4, 215-45	4.9	16
17	Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5483-95	12.9	12
16	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , <b>2007</b> , 12, 155-63	3.7	9
15	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 109-109	2.2	5
14	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. <i>Blood</i> , <b>2004</b> , 104, 785-785	2.2	4
13	Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.. <i>Blood</i> , <b>2006</b> , 108, 88-88	2.2	4
12	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , <b>2004</b> , 104, 2405-2405	2.2	2
11	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 219, 113435	6.8	2
10	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 374-5		1
9	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , <b>2005</b> , 106, 3378-3378	2.2	1
8	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. <i>Blood</i> , <b>2004</b> , 104, 285-285	2.2	1
7	Inference and Analysis of Gene Regulatory Networks in R <b>2016</b> , 289-306		0
6	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 1089-1108	1.1	
5	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, S40-S42		

- 4 Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. *Blood*, **2004**, 104, 2401-2401 2.2
- 3 Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. *Blood*, **2004**, 104, 764-764 2.2
- 2 TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. *Blood*, **2008**, 112, 2737-2737 2.2
- 1 Novel Agents in Multiple Myeloma **2013**, 215-228